Brief: Silo Pharma Secures Exclusive Global License For Alzheimer's Therapeutic
16/07/2024 11:35
July 16 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA SECURES EXCLUSIVE GLOBAL LICENSE FOR
ALZHEIMER'S
THERAPEUTIC
* SILO PHARMA INC: LICENSE AGREEMENT TO FURTHER DEVELOP,
MANUFACTURE, AND COMMERCIALIZE ALZHEIMER'S DRUG SPC-14
* SILO PHARMA- INTENDS TO UTILIZE FDA'S STREAMLINED
505(B)(2)
PATHWAY FOR SPC-14, WHICH WOULD SHORTEN CLINICAL TIMELINES &
REDUCE DRUG DEVELOPMENT COSTS
Source text for Eikon: ID:nGNX8LyvRG
Further company coverage: SILO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement